DK2215223T3 - Rationelt konstruerede enkeltkæde-meganucleaser med ikke-palindrome genkendelsessekvenser - Google Patents
Rationelt konstruerede enkeltkæde-meganucleaser med ikke-palindrome genkendelsessekvenserInfo
- Publication number
- DK2215223T3 DK2215223T3 DK08845549.8T DK08845549T DK2215223T3 DK 2215223 T3 DK2215223 T3 DK 2215223T3 DK 08845549 T DK08845549 T DK 08845549T DK 2215223 T3 DK2215223 T3 DK 2215223T3
- Authority
- DK
- Denmark
- Prior art keywords
- mechanucleases
- single chain
- recognition sequences
- constructed single
- rationally constructed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US124707P | 2007-10-31 | 2007-10-31 | |
| PCT/US2008/082072 WO2009059195A2 (en) | 2007-10-31 | 2008-10-31 | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2215223T3 true DK2215223T3 (da) | 2013-07-22 |
Family
ID=40591777
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08845549.8T DK2215223T3 (da) | 2007-10-31 | 2008-10-31 | Rationelt konstruerede enkeltkæde-meganucleaser med ikke-palindrome genkendelsessekvenser |
| DK16163925.7T DK3098309T3 (da) | 2007-10-31 | 2008-10-31 | Rationelt designet enkeltkædet meganuclease med ikke-palindrome genkendelsessekvenser |
| DK13165733.0T DK2660317T3 (en) | 2007-10-31 | 2008-10-31 | Rationally designed single-chain meganucleases with non-palindromic recognition sequences |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16163925.7T DK3098309T3 (da) | 2007-10-31 | 2008-10-31 | Rationelt designet enkeltkædet meganuclease med ikke-palindrome genkendelsessekvenser |
| DK13165733.0T DK2660317T3 (en) | 2007-10-31 | 2008-10-31 | Rationally designed single-chain meganucleases with non-palindromic recognition sequences |
Country Status (8)
| Country | Link |
|---|---|
| US (10) | US8445251B2 (enExample) |
| EP (4) | EP3098309B1 (enExample) |
| JP (7) | JP5761996B2 (enExample) |
| AU (1) | AU2008318430A1 (enExample) |
| CA (1) | CA2704383A1 (enExample) |
| DK (3) | DK2215223T3 (enExample) |
| ES (3) | ES2422291T3 (enExample) |
| WO (1) | WO2009059195A2 (enExample) |
Families Citing this family (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009095742A1 (en) | 2008-01-31 | 2009-08-06 | Cellectis | New i-crei derived single-chain meganuclease and uses thereof |
| US8206965B2 (en) † | 2002-03-15 | 2012-06-26 | Cellectis S.A. | Hybrid and single chain meganucleases and use thereof |
| ES2422291T3 (es) | 2007-10-31 | 2013-09-10 | Prec Biosciences Inc | Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas |
| WO2011064751A1 (en) | 2009-11-27 | 2011-06-03 | Basf Plant Science Company Gmbh | Chimeric endonucleases and uses thereof |
| AU2010325563B2 (en) | 2009-11-27 | 2017-02-02 | Basf Plant Science Company Gmbh | Chimeric endonucleases and uses thereof |
| CN102725412B (zh) | 2009-11-27 | 2017-09-22 | 巴斯夫植物科学有限公司 | 优化的内切核酸酶及其用途 |
| US20130198897A1 (en) | 2010-03-22 | 2013-08-01 | Philip Morris Products S.A. | Modifying enzyme activity in plants |
| WO2012138901A1 (en) * | 2011-04-05 | 2012-10-11 | Cellectis Sa | Method for enhancing rare-cutting endonuclease efficiency and uses thereof |
| EP3683319A1 (en) | 2011-06-01 | 2020-07-22 | Precision Biosciences, Inc. | Methods and products for producing engineered mammalian cell lines with amplified transgenes |
| EP2612918A1 (en) | 2012-01-06 | 2013-07-10 | BASF Plant Science Company GmbH | In planta recombination |
| US20150184173A1 (en) | 2012-05-04 | 2015-07-02 | E I Du Pont De Nemours And Company | Compositions and methods comprising sequences having meganuclease activity |
| AU2015229299A1 (en) | 2014-03-12 | 2016-09-22 | Precision Biosciences, Inc. | Dystrophin gene exon deletion using engineered nucleases |
| EA201790551A1 (ru) | 2014-09-07 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору |
| US20180344817A1 (en) | 2015-05-01 | 2018-12-06 | Precision Biosciences, Inc. | Precise deletion of chromosomal sequences in vivo and treatment of nucleotide repeat expansion disorders using engineered nucleases |
| DK3447075T3 (da) | 2015-05-15 | 2023-11-13 | Massachusetts Gen Hospital | Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien |
| US10662440B2 (en) | 2015-06-19 | 2020-05-26 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
| JP6980534B2 (ja) | 2015-06-25 | 2021-12-15 | ザ チルドレンズ メディカル センター コーポレーション | 造血幹細胞の増大、富化、および維持に関する方法および組成物 |
| WO2017024407A1 (en) | 2015-08-11 | 2017-02-16 | The Royal Institution For The Advancement Of Learning/Mcgill University | Peptidic tgf-beta antagonists |
| CA2997909A1 (en) | 2015-09-08 | 2017-03-16 | Precision Biosciences, Inc. | Treatment of retinitis pigmentosa using engineered meganucleases |
| ES2803728T3 (es) | 2015-10-05 | 2021-01-29 | Prec Biosciences Inc | Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado |
| ES2768984T3 (es) | 2015-10-05 | 2020-06-24 | Prec Biosciences Inc | Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas |
| US20190017075A1 (en) | 2015-12-23 | 2019-01-17 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| US11274288B2 (en) | 2016-02-16 | 2022-03-15 | Emendobio Inc. | Compositions and methods for promoting homology directed repair mediated gene editing |
| WO2017161001A1 (en) | 2016-03-15 | 2017-09-21 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| EP3448380B1 (en) | 2016-04-27 | 2021-12-01 | University Of Puerto Rico | 1,5-disubstituted 1,2,3-triazoles are inhibitors of rac/cdc42 gtpases |
| EP3452583B1 (en) | 2016-05-03 | 2021-10-27 | Precision Biosciences, Inc. | Engineered nucleases useful for treatment of hemophilia a |
| AR108853A1 (es) | 2016-06-22 | 2018-10-03 | Univ North Carolina State | Método para aumentar la eficacia en el uso de nitrógeno y/o la eficiencia en la utilización del nitrógeno en las plantas |
| CA3031785A1 (en) * | 2016-07-25 | 2018-02-01 | Bluebird Bio, Inc. | Bcl11a homing endonuclease variants, compositions, and methods of use |
| US20190262398A1 (en) | 2016-08-23 | 2019-08-29 | Bluebird Bio, Inc. | Tim3 homing endonuclease variants, compositions, and methods of use |
| SG11201901757YA (en) | 2016-09-08 | 2019-03-28 | Bluebird Bio Inc | Pd-1 homing endonuclease variants, compositions, and methods of use |
| DK3757120T3 (da) | 2016-10-04 | 2022-07-25 | Prec Biosciences Inc | Co-stimulerende domæner til anvendelse i genetisk modificerede celler |
| KR20230010826A (ko) * | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| US11530395B2 (en) | 2016-10-17 | 2022-12-20 | 2Seventy Bio, Inc. | TGFBetaR2 endonuclease variants, compositions, and methods of use |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| US10457683B2 (en) | 2017-04-12 | 2019-10-29 | Magenta Therapeutics Inc. | Aryl hydrocarbon receptor antagonists and uses thereof |
| EP4269596A3 (en) * | 2017-04-21 | 2024-02-14 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the pcsk9 gene |
| US20200190541A1 (en) | 2017-04-28 | 2020-06-18 | Precision Biosciences, Inc. | Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells |
| JP7170666B2 (ja) | 2017-05-08 | 2022-11-14 | プレシジョン バイオサイエンシズ，インク． | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
| IL270776B2 (en) | 2017-05-25 | 2024-11-01 | Bluebird Bio Inc | Cblb endonuclease variants, compositions, and methods of use |
| US12139718B2 (en) | 2017-06-23 | 2024-11-12 | University Of Kentucky Research Foundation | Methods of decreasing total alkaloid content in tobacco |
| EP4775669A2 (en) | 2017-06-30 | 2026-07-15 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| JP2020529206A (ja) | 2017-07-31 | 2020-10-08 | アール・ジエイ・レイノルズ・タバコ・カンパニー | 植物におけるウイルスベースの遺伝子編集のための方法及び組成物 |
| EP3692057B9 (en) | 2017-10-03 | 2023-10-04 | Precision BioSciences, Inc. | Modified epidermal growth factor receptor peptides for use in genetically-modified cells |
| US11779654B2 (en) | 2017-10-04 | 2023-10-10 | 2Seventy Bio, Inc. | PCSK9 endonuclease variants, compositions, and methods of use |
| WO2019075360A1 (en) | 2017-10-13 | 2019-04-18 | Selecta Biosciences, Inc. | METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES |
| AU2018358054A1 (en) | 2017-10-31 | 2020-05-07 | Magenta Therapeutics Inc. | Compositions and methods for hematopoietic stem and progenitor cell transplant therapy |
| US20190314407A1 (en) | 2017-10-31 | 2019-10-17 | Magenta Therapeutics Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells |
| EP3704238B1 (en) | 2017-11-01 | 2024-01-03 | Precision Biosciences, Inc. | Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a |
| IL275077B2 (en) | 2017-12-06 | 2025-02-01 | Magenta Therapeutics Inc | Dosing regimens for mobilization of hematopoietic stem and progenitor cells. |
| US20210002621A1 (en) * | 2017-12-20 | 2021-01-07 | Bluebird Bio, Inc. | Ctla4 homing endonuclease variants, compositions, and methods of use |
| EP3735412B1 (en) | 2018-01-03 | 2024-02-21 | EdiGene Biotechnology, Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders |
| UA128937C2 (uk) | 2018-01-09 | 2024-12-04 | Сайбас Юес Ллс | Рослина brassica napus, що має знижену сприйнятливість до розстріскування плодів до збирання урожаю, та спосіб її одержання |
| JP2021515037A (ja) | 2018-02-26 | 2021-06-17 | アントルクス，インコーポレーテッド | 寛容原性リポソーム及びその使用方法 |
| EA202092382A1 (ru) | 2018-04-04 | 2021-02-02 | САЙБАС ЮЭс ЛЛС | Гены fad2 и мутации |
| IT201800004253A1 (it) | 2018-04-05 | 2019-10-05 | Composizioni e metodi per il trattamento della tachicardia ventricolare polimorfa catecolaminergica dominante ereditaria. | |
| KR102617818B1 (ko) | 2018-04-12 | 2023-12-27 | 프리시젼 바이오사이언시스 인코포레이티드 | 인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| WO2019210213A1 (en) * | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bruton's tyrosine kinase homing endonuclease variants, compositions, and methods of use |
| CN112368021B (zh) | 2018-06-14 | 2025-02-21 | 2赛文缇生物公司 | Cd79a嵌合抗原受体 |
| GB201812603D0 (en) | 2018-08-02 | 2018-09-19 | British American Tobacco Investments Ltd | Method |
| JP2021536458A (ja) | 2018-09-04 | 2021-12-27 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | アリール炭化水素レセプター・アンタゴニスト及び使用方法 |
| WO2020072059A1 (en) | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
| GB201817971D0 (en) | 2018-11-02 | 2018-12-19 | British American Tobacco Investments Ltd | Method |
| GB201818715D0 (en) | 2018-11-16 | 2019-01-02 | British American Tobacco Investments Ltd | Method |
| JP2022513750A (ja) | 2018-12-10 | 2022-02-09 | ２セブンティ バイオ インコーポレイテッド | ホーミングエンドヌクレアーゼバリアント |
| CA3122094A1 (en) | 2018-12-10 | 2020-06-18 | Bluebird Bio, Inc. | Pdcd-1 homing endonuclease variants |
| EP3898661A1 (en) | 2018-12-21 | 2021-10-27 | Precision BioSciences, Inc. | Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria |
| GB201900940D0 (en) | 2019-01-23 | 2019-03-13 | British American Tobacco Investments Ltd | Method |
| EP4332115A3 (en) | 2019-04-03 | 2024-05-29 | Precision Biosciences, Inc. | Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) |
| EP3947646A1 (en) | 2019-04-05 | 2022-02-09 | Precision BioSciences, Inc. | Methods of preparing populations of genetically-modified immune cells |
| CN114026228A (zh) | 2019-05-07 | 2022-02-08 | 精密生物科学公司 | 用于识别序列的工程化大范围核酸酶的优化 |
| GB201906768D0 (en) | 2019-05-14 | 2019-06-26 | British American Tobacco Investments Ltd | Method |
| CA3141863A1 (en) | 2019-05-28 | 2020-12-03 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
| GB201909562D0 (en) | 2019-07-03 | 2019-08-14 | British American Tobacco Investments Ltd | Method |
| GB201909563D0 (en) | 2019-07-03 | 2019-08-14 | British American Tobacco Investments Ltd | Method |
| WO2021035054A1 (en) | 2019-08-20 | 2021-02-25 | Precision Biosciences, Inc. | Lymphodepletion dosing regimens for cellular immunotherapies |
| US20220411479A1 (en) | 2019-10-30 | 2022-12-29 | Precision Biosciences, Inc. | Cd20 chimeric antigen receptors and methods of use for immunotherapy |
| WO2021087406A1 (en) | 2019-11-01 | 2021-05-06 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progentor cells |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| EP3835309A1 (en) | 2019-12-13 | 2021-06-16 | KWS SAAT SE & Co. KGaA | Method for increasing cold or frost tolerance in a plant |
| WO2021158915A1 (en) | 2020-02-06 | 2021-08-12 | Precision Biosciences, Inc. | Recombinant adeno-associated virus compositions and methods for producing and using the same |
| JP2023521055A (ja) | 2020-04-09 | 2023-05-23 | アール・ジエイ・レイノルズ・タバコ・カンパニー | ニコチアナ・タバカムにおけるニコチンレベルの調整方法 |
| AU2021263754A1 (en) | 2020-04-27 | 2022-12-01 | Ensoma, Inc. | Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo |
| WO2021231259A1 (en) | 2020-05-11 | 2021-11-18 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
| IL298138A (en) | 2020-05-12 | 2023-01-01 | Univ Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| EP4150068A1 (en) | 2020-05-12 | 2023-03-22 | Precision BioSciences, Inc. | Treatment of retinitis pigmentosa using improved engineered meganucleases |
| EP4192875A1 (en) | 2020-08-10 | 2023-06-14 | Precision BioSciences, Inc. | Antibodies and fragments specific for b-cell maturation antigen and uses thereof |
| US20240011003A1 (en) | 2020-08-21 | 2024-01-11 | Precision Biosciences, Inc. | Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene |
| US20230365995A1 (en) | 2020-10-07 | 2023-11-16 | Precision Biosciences, Inc. | Lipid nanoparticle compositions |
| MX2023005113A (es) | 2020-10-29 | 2023-08-04 | Univ Pennsylvania | Cápsides de aav y composiciones que las contienen. |
| KR20250099412A (ko) | 2020-11-12 | 2025-07-01 | 프리시젼 바이오사이언시스 인코포레이티드 | 디스트로핀 유전자 내의 인식 서열에 대해 특이성을 갖는 조작된 메가뉴클레아제 |
| CA3172161A1 (en) | 2021-01-08 | 2022-07-14 | James Jefferson Smith | Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene |
| WO2022165111A1 (en) | 2021-01-28 | 2022-08-04 | Precision Biosciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
| WO2022197776A1 (en) | 2021-03-16 | 2022-09-22 | Magenta Therapeutics, Inc. | Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients |
| WO2022226316A1 (en) | 2021-04-22 | 2022-10-27 | Precision Biosciences, Inc. | Compositions and methods for generating male sterile plants |
| IL307834A (en) | 2021-04-22 | 2023-12-01 | Prec Biosciences Inc | Transgenic meganonucleases targeting human mitochondrial genomes |
| US20240200046A1 (en) * | 2021-04-22 | 2024-06-20 | Precision Biosciences, Inc. | Engineered meganucleases that target human mitochondrial genomes |
| TW202309066A (zh) | 2021-04-27 | 2023-03-01 | 賓州大學委員會 | 衍生自豬的腺相關病毒衣殼及其用途 |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| MX2024004812A (es) | 2021-10-19 | 2024-07-15 | Prec Biosciences Inc | Métodos de edición génica para el tratamiento de la deficiencia de alfa-1 antitripsina (aat). |
| AU2022368911A1 (en) | 2021-10-19 | 2024-05-30 | Precision Biosciences, Inc. | Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency |
| WO2023087019A2 (en) | 2021-11-15 | 2023-05-19 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| KR20240132132A (ko) | 2022-02-03 | 2024-09-02 | 니코벤처스 트레이딩 리미티드 | 담배 식물들에서 알칼로이드 함량을 조절하는 방법 |
| WO2023148478A1 (en) | 2022-02-03 | 2023-08-10 | Nicoventures Trading Limited | Method of modulating alkaloid content in tobacco plants |
| WO2023148475A1 (en) | 2022-02-04 | 2023-08-10 | Nicoventures Trading Limited | Method of modulating alkaloid content in tobacco plants |
| US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| GB202205148D0 (en) | 2022-04-07 | 2022-05-25 | Nicoventures Trading Ltd | Method |
| GB202205149D0 (en) | 2022-04-07 | 2022-05-25 | Nicoventures Trading Ltd | Method |
| GB202205561D0 (en) | 2022-04-14 | 2022-06-01 | Nicoventures Trading Ltd | Method |
| GB202205562D0 (en) | 2022-04-14 | 2022-06-01 | Nicoventures Trading Ltd | Method |
| GB202206109D0 (en) | 2022-04-27 | 2022-06-08 | Nicoventures Trading Ltd | Method |
| GB202206107D0 (en) | 2022-04-27 | 2022-06-08 | Nicoventures Trading Ltd | Method |
| WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
| WO2024015966A2 (en) | 2022-07-15 | 2024-01-18 | The Trustees Of The University Of Pennsylvania | Recombinant aav having aav clade d and clade e capsids and compositions containing same |
| WO2024056902A2 (en) | 2022-09-16 | 2024-03-21 | Christopher Shaw | Compositions and methods for treating neurological diseases |
| WO2024097639A1 (en) | 2022-10-31 | 2024-05-10 | Modernatx, Inc. | Hsa-binding antibodies and binding proteins and uses thereof |
| US20260191905A1 (en) | 2022-12-01 | 2026-07-09 | Modernatx, Inc. | Gpc3-specific antibodies, binding domains, and related proteins and uses thereof |
| AU2023392154A1 (en) | 2022-12-14 | 2025-06-26 | King's College London | Compositions and methods for treating neurological diseases |
| IL321936A (en) | 2023-01-05 | 2025-09-01 | Prec Biosciences Inc | Optimized engineered meganucleases with specificity for the human T-cell receptor alpha constant region gene |
| GB202300905D0 (en) | 2023-01-20 | 2023-03-08 | Nicoventures Trading Ltd | Method |
| WO2024161022A2 (en) | 2023-02-03 | 2024-08-08 | King's College London | Compositions and methods for treating neurological diseases |
| KR20250141243A (ko) | 2023-02-06 | 2025-09-26 | 블루록 테라퓨틱스 엘피 | 데그론 융합 단백질 및 그의 생산 및 사용 방법 |
| GB202303077D0 (en) | 2023-03-02 | 2023-04-19 | Univ Oslo | Brassica plants with improved seed retention |
| AU2024229544A1 (en) | 2023-03-02 | 2025-10-16 | Alloy Therapeutics, Inc. | Anti-cd22 antibodies and uses thereof |
| CN121311497A (zh) | 2023-04-14 | 2026-01-09 | 精密生物科学公司 | 肌肉特异性表达盒 |
| WO2024216116A1 (en) | 2023-04-14 | 2024-10-17 | Precision Biosciences, Inc. | Muscle-specific expression cassettes |
| WO2024236547A1 (en) | 2023-05-18 | 2024-11-21 | Inceptor Bio, Llc | Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof |
| WO2025046513A1 (en) | 2023-08-29 | 2025-03-06 | Inceptor Bio, Llc | Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof |
| WO2025083169A1 (en) | 2023-10-17 | 2025-04-24 | Tenpoint Therapeutics Limited | Combination of a vegf inhibitor and a complement pathway inhibitor for treating ocular disorders |
| WO2025101946A1 (en) | 2023-11-08 | 2025-05-15 | Precision Biosciences, Inc. | Polypeptide linkers for use in engineered meganucleases |
| WO2025126153A2 (en) | 2023-12-14 | 2025-06-19 | Aviadobio Ltd. | Compositions and methods for treating sod1-mediated neurological diseases |
| WO2025233894A1 (en) | 2024-05-09 | 2025-11-13 | University Of Miami | Engineered meganucleases that target human mitochondrial genomes |
| WO2026006495A1 (en) | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-wt1/hla-a2 antibody and uses thereof |
| WO2026006492A2 (en) | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anti-prame/hla-a2 antibodies and uses thereof |
| WO2026028165A1 (en) | 2024-08-01 | 2026-02-05 | Precision Biosciences, Inc. | Engineered meganucleases having specificity for recognition sequences in the c9orf72 gene |
| WO2026047626A1 (en) | 2024-08-30 | 2026-03-05 | Inceptor Bio, Llc | Compositions and methods involving immune cells engineered for binding bispecific antibodies for use in cell therapy |
| WO2026154123A1 (en) | 2025-01-17 | 2026-07-23 | Aviadobio Limited | Compositions and methods for treating neurological diseases |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3751873T2 (de) | 1986-04-09 | 1997-02-13 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US6156304A (en) | 1990-12-20 | 2000-12-05 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Gene transfer for studying and treating a connective tissue of a mammalian host |
| US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
| US5997861A (en) | 1994-10-31 | 1999-12-07 | Burstein Laboratories, Inc. | Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| US6593308B2 (en) | 1999-12-03 | 2003-07-15 | The Regents Of The University Of California | Targeted drug delivery with a hyaluronan ligand |
| AU2002317771A1 (en) * | 2001-06-05 | 2002-12-16 | Cellectis | Methods for modifying the cpg content of polynucleotides |
| EP1483298A4 (en) * | 2002-02-11 | 2007-03-14 | Zymogenetics Inc | MATERIALS AND METHODS FOR PREPARING DIMERED GROWTH FACTORS |
| WO2009095742A1 (en) | 2008-01-31 | 2009-08-06 | Cellectis | New i-crei derived single-chain meganuclease and uses thereof |
| US8206965B2 (en) * | 2002-03-15 | 2012-06-26 | Cellectis S.A. | Hybrid and single chain meganucleases and use thereof |
| US20060206949A1 (en) | 2003-01-28 | 2006-09-14 | Sylvain Arnould | Custom-made meganuclease and use thereof |
| JP4095622B2 (ja) * | 2004-03-31 | 2008-06-04 | キヤノン株式会社 | 金結合性複合タンパク質 |
| EP1591521A1 (en) * | 2004-04-30 | 2005-11-02 | Cellectis | I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof |
| WO2006097784A1 (en) | 2005-03-15 | 2006-09-21 | Cellectis | I-crei meganuclease variants with modified specificity, method of preparation and uses thereof |
| ATE466933T1 (de) | 2005-03-15 | 2010-05-15 | Cellectis | I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung |
| WO2007034262A1 (en) | 2005-09-19 | 2007-03-29 | Cellectis | Heterodimeric meganucleases and use thereof |
| EP1764414A1 (en) * | 2005-09-17 | 2007-03-21 | Icon Genetics AG | Plant viral particles comprising a plurality of fusion proteins consisting of a plant viral coat protein, a peptide linker and a recombinant protein and use of such plant viral particles for protein purification |
| DK3246403T3 (da) | 2005-10-18 | 2020-10-26 | Prec Biosciences | Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet |
| WO2007060495A1 (en) | 2005-10-25 | 2007-05-31 | Cellectis | I-crei homing endonuclease variants having novel cleavage specificity and use thereof |
| WO2007049095A1 (en) | 2005-10-25 | 2007-05-03 | Cellectis | Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof |
| AU2006320246A1 (en) * | 2005-11-29 | 2007-06-07 | Virginia Commonwealth University | Polyvalent chimeric OspC vaccinogen and diagnostic antigen |
| WO2007093836A1 (en) | 2006-02-13 | 2007-08-23 | Cellectis | Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof |
| GB0603099D0 (en) * | 2006-02-16 | 2006-03-29 | Lontra Environmental Technolog | Rotary piston and cylinder devices |
| WO2008010009A1 (en) | 2006-07-18 | 2008-01-24 | Cellectis | Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof |
| WO2008059317A1 (en) | 2006-11-14 | 2008-05-22 | Cellectis | Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereof |
| SG176487A1 (en) | 2006-11-14 | 2011-12-29 | Cellectis | Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereof |
| WO2008093152A1 (en) | 2007-02-01 | 2008-08-07 | Cellectis | Obligate heterodimer meganucleases and uses thereof |
| AU2007347328B2 (en) | 2007-02-19 | 2013-03-07 | Cellectis | LAGLIDADG homing endonuclease variants having novel substrate specificity and use thereof |
| WO2008102199A1 (en) * | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| WO2008149176A1 (en) * | 2007-06-06 | 2008-12-11 | Cellectis | Meganuclease variants cleaving a dna target sequence from the mouse rosa26 locus and uses thereof |
| CA2691440A1 (en) | 2007-06-29 | 2009-01-08 | Pioneer Hi-Bred International, Inc. | Methods for altering the genome of a monocot plant cell |
| ES2422291T3 (es) | 2007-10-31 | 2013-09-10 | Prec Biosciences Inc | Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas |
| WO2009074842A1 (en) | 2007-12-13 | 2009-06-18 | Cellectis | Improved chimeric meganuclease enzymes and uses thereof |
-
2008
- 2008-10-31 ES ES08845549T patent/ES2422291T3/es active Active
- 2008-10-31 DK DK08845549.8T patent/DK2215223T3/da active
- 2008-10-31 JP JP2010532293A patent/JP5761996B2/ja active Active
- 2008-10-31 DK DK16163925.7T patent/DK3098309T3/da active
- 2008-10-31 EP EP16163925.7A patent/EP3098309B1/en active Active
- 2008-10-31 WO PCT/US2008/082072 patent/WO2009059195A2/en not_active Ceased
- 2008-10-31 EP EP19167904.2A patent/EP3578646B1/en active Active
- 2008-10-31 AU AU2008318430A patent/AU2008318430A1/en not_active Abandoned
- 2008-10-31 EP EP08845549.8A patent/EP2215223B1/en active Active
- 2008-10-31 CA CA2704383A patent/CA2704383A1/en not_active Abandoned
- 2008-10-31 EP EP13165733.0A patent/EP2660317B1/en active Active
- 2008-10-31 ES ES16163925T patent/ES2732735T3/es active Active
- 2008-10-31 ES ES13165733.0T patent/ES2575412T3/es active Active
- 2008-10-31 DK DK13165733.0T patent/DK2660317T3/en active
-
2010
- 2010-04-30 US US12/771,163 patent/US8445251B2/en active Active
-
2013
- 2013-05-20 US US13/897,923 patent/US20130267009A1/en not_active Abandoned
-
2015
- 2015-05-28 US US14/723,840 patent/US20150337335A1/en not_active Abandoned
- 2015-06-08 JP JP2015115646A patent/JP6050861B2/ja active Active
- 2015-09-18 US US14/858,989 patent/US9434931B2/en active Active
- 2015-09-18 US US14/858,986 patent/US9340777B2/en active Active
-
2016
- 2016-04-19 US US15/132,941 patent/US10041053B2/en active Active
- 2016-09-30 JP JP2016193485A patent/JP2017051190A/ja active Pending
-
2018
- 2018-07-02 US US16/025,747 patent/US20180340160A1/en not_active Abandoned
- 2018-11-22 JP JP2018219205A patent/JP2019062898A/ja active Pending
-
2020
- 2020-10-23 US US17/079,377 patent/US20210054354A1/en not_active Abandoned
- 2020-11-27 JP JP2020196770A patent/JP2021052770A/ja active Pending
-
2022
- 2022-11-25 JP JP2022187981A patent/JP2023029894A/ja active Pending
-
2023
- 2023-03-17 US US18/185,726 patent/US12351839B2/en active Active
-
2024
- 2024-10-24 JP JP2024187133A patent/JP2025028832A/ja active Pending
-
2025
- 2025-01-17 US US19/029,758 patent/US20250154485A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3098309T3 (da) | Rationelt designet enkeltkædet meganuclease med ikke-palindrome genkendelsessekvenser | |
| DE602007005217D1 (de) | Fahrradkette | |
| BRPI0914889A2 (pt) | peptídeo glp-1 adicionado de cadeia oligossacarídica | |
| EP2209394A4 (en) | Armtasche | |
| BRPI0811497A2 (pt) | Arquitetura multiprocessador com encadeamento otimizado | |
| DE502008000295D1 (de) | Nockenwelle | |
| BRPI0718796A2 (pt) | Nucleotídeo | |
| DK2087307T3 (da) | Med afstand anbragt letvægtskompositpanser | |
| EP2262892A4 (en) | EXPRESSION OF HETEROLOGOUS SEQUENCES | |
| DE602007004088D1 (de) | Kettenförderer | |
| EP2433766A4 (en) | CHAINSAW | |
| EP2162436A4 (en) | NEW CASE OF RENININHIBITORS | |
| FR2910111B3 (fr) | Tronconneuse | |
| EP2318537A4 (en) | OPTIMIZED PROMOTER SEQUENCE | |
| DE112008002937A5 (de) | Geräuscharmer Kettentrieb | |
| HUE038633T2 (hu) | MMP-14 specifikus hasítási szekvencia | |
| FIU20060412U0 (fi) | Suojaliivi | |
| AT508202A3 (de) | Metallriemenkalander | |
| AT504336B8 (de) | Kettenrad | |
| DE112009000779A5 (de) | Galvanisierungsverfahren | |
| ES1066538Y (es) | Llavero | |
| ES1068660Y (es) | Llavero | |
| UA15228S (uk) | Медальйон з ланцюжком | |
| FI20065600A0 (fi) | Kampiakseli | |
| GB0805010D0 (en) | Chain and sprocket guard |